Candida Albicans Infection, Candida Infection, Candida Systemic
Conditions
Brief summary
This is a virtual, double-blind, two-arm, randomized, placebo-controlled clinical trial that will last 12 weeks. Participants will take the CanXida Remove Candida Cleansing Formula RMV or a placebo product daily and complete questionnaires at Baseline, Week 6, and Week 12. Candida microbiome testing will be conducted via stool sample at Baseline and Week 12. The participants will all be blinded to the name of the test brand.
Interventions
DIETARY_SUPPLEMENTCanXida Remove (Formula RMV)
Supplement composed of a 12 ingredient anti-fungal, anti-bacterial & anti-parasite formula.
OTHERPlacebo
Placebo product containing Dicalcium Phosphate, Magnesium Stearate, Stearic Acid, Croscarmellose Sodium, and Silica.
Sponsors
Citruslabs
CanXida
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Caregiver, Investigator)
Masking description
This study will be double-blinded in that the study participants and the Citruslabs team will be blinded to the intervention or product allocation. Only the sponsor will know which product contains the active ingredients. After the study analysis is complete, the allocation will be unblinded.
Intervention model description
Group A = the intervention group Group B = the placebo group
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Aged between 18-50. 2. Female. 3. Self-reported recurrent vaginal issues, including: * Itching and irritation in and around the vaginal area. * Burning sensation during urination or sexual intercourse. * Abnormal discharge (e.g. thicker, white, and curd-like in appearance, odorless, or with a mild yeasty smell. * Redness and swelling of the vulva and surrounding skin * Pain or discomfort in the vaginal area or lower abdomen. * Urinary tract infections * Vaginal thrush 4. May also experience issues with fatigue, lethargy, and gut or digestive issues. 5. Willing to provide two stool samples during the study. 6. Willing to adhere to the study protocol. 7. Willing to avoid introducing any products or any new forms of regular medication or supplements that target candida overgrowth, gut health, or vaginal health for the duration of the study.
Exclusion criteria
1. Anyone with severe chronic conditions including oncological conditions, psychiatric disease, diabetes, or other. 2. Anyone with known severe allergic reactions or is allergic to the test product or placebo ingredients. 3. Currently taking any antibiotics or will be during the trial period. 4. Anymore diagnosed with a sexually transmitted disease within the last three months e.g. Chlamydia, trichomoniasis, gonorrhea, genital herpes 5. Women who are pregnant, breastfeeding, or attempting to become pregnant. 6. Having any planned invasive medical procedures during the study period. 7. Currently participating in any other clinical study. 8. History of substance abuse. 9. Unwilling to follow the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in growth of candida in the gut. [Timeframe: Baseline to Week 12] | 12 weeks | Measured via gut microbiome analysis. Participants will provide a stool sample for the analysis. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in vaginal health symptoms. [Timeframe: Baseline to Week 12] | 12 weeks | Measured via study-specific questionnaires. Questionnaires will use a Likert scale (0-5 scale) to measure changes in vaginal itching, vaginal discharge, vaginal discomfort. On the scale, 0= the least favourable score and 5= the most favourable score. |
| Changes in scores on the Gastrointestinal Symptom Rating Scale (GSRS). [Timeframe: Baseline to Week 12] | 12 weeks | The GSRS is a disease-specific instrument of 15 items combined into five symptom clusters depicting Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms. |
| Changes in scores on the Bristol Stool Scale. [Timeframe: Baseline to Week 12] | 12 weeks | The Bristol Stool Scale is a scale that classifies stools, ranging from the hardest to the softest. Experts consider types 1 and 2 to be uncharacteristically hard and indicative of constipation, while types 6 and 7 are unusually loose and may indicate diarrhea. Medical professionals generally consider types 3, 4, and 5 to be the most typical. |
| Changes in self-reported energy levels. [Timeframe: Baseline to Week 12] | 12 weeks | Measured via study-specific questionnaires using a 5-point Likert scale. 0= the most favourable and 5= the least favourable response. |
Countries
United States
Outcome results
None listed